Search filters

Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 90
  • 14
  • 168
  • 694
  • 444
  • 14
  • 31
  • 1
  • 4
  • 646

Found 696 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke
99 years or below
All genders
Phase 3
Reliance Agreement Request
 UPCC 15217: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
18 years - 99 years
All genders
Phase 3
The main purpose of this study is to find out if the study drug ARQ 087 is safe and effective to use in patients with intrahepatic cholangiocarcinoma.
 UPCC 02818: A Phase I/IB Study of Avelumab in Combination with Gemcitabine for Advanced Renal Cell Carcinoma with Sarcomatoid Differentiation
99 years or below
All genders
Phase 1
This study is being done because doctors are trying to develop better methods for treating kidney cancer that has spread to other organs in the body. This study will evaluate the initial safety and effectiveness of an investigational drug, avelumab, given in combination with a chemotherapy drug (gemcitabine) that is …
 UPCC 05418: A Multicenter  Double-Blind  Randomized  Placebo-Controlled  Phase III Study of Idasanutlin  an MDM2 Antagonist  with Cytarabine Versus Cytarabine Plus Placebo in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
99 years or below
All genders
Phase 3
The purpose of this study is to compare the effects, good or bad, of idasanutlin plus cytarabine (chemotherapy) versus placebo (an inactive substance that looks like idasanutlin) plus cytarabine on patients with relapsed or refractory Acute Myeloid Leukemia (AML) to find out which is better.
99 years or below
All genders
Phase 2
To evaluate progression-free survival (PFS) using traditional RECIST critiera with the combination of fulvestrant and palbociclib vs. fulvestrant alone in patients with advanced HR+/HER2- breast cancer that has progressed despite prior CDK4/6 inhibition and endocrine therapy.
 Managed Access Program (MAP) to provide access to CTL019  for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
99 years or below
All genders
The purpose of this Treatment Plan is to allow access to tisagenlecleucel (CTL019) for eligible patients diagnosed with acute lymphoblastic leukemia (ALL) or large b-cell lymphomas who are unable to receive commercially manufactured product due to failure of the incoming apheresis material or outgoing product to meet the commercial specifications …
99 years or below
All genders
Phase 2
The purpose of this study is to identify the best dose of entinostat when combined with bevacizumab and atezolizumab and to find out what side effects are caused by the combination of these drugs in patients with renal cell carcinoma.
 An Open-Label Phase 2 Proof or Concept Study in Patients with C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated with ACH-0144471
17 years - 65 years
All genders
Phase 2
This is an open-label study of 12 months of dosing with ACH-0144471. The study will enroll patients with biopsy-confirmed C3G or IC-MPGN who meet eligibility criteria for this study. There will be a multi-step screening process. At the initial screening visit, all screening eligibility assessments, except the renal biopsy, will …
99 years or below
All genders
Veno-arterial (VA) extra-corporeal membrane oxygenation (ECMO) is indicated as a haemodynamic rescue strategy in decompensated acute or chronic heart failure presenting as cardiogenic shock. VA ECMO has a number of effects on the circulation including (i) perfusing end-organs, (ii) ventricular unloading, and (iii) improved coronary perfusion. It is a bridge …
 Light Treatment Effectiveness (LITE) Study
12 years - 99 years
All genders
Phase 4
Phototherapy delivered at home or the office are both common treatments for psoriasis but it is not known how well they compare to one another. The purpose of this study is to compare the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based NB-UVB phototherapy …
141 - 150 of 696